Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis.

Milo Gatti Elisabetta Poluzzi Fabrizio de Ponti Emanuel Raschi

Published in: Drug safety (2021)

Different drug properties previously linked to the occurrence of DILI may partially explain the reporting pattern observed with UPA. Our "bedside-to-bench" approach may support regulators in the risk-benefit assessment of UPA.

Keyphrases

drug induced
liver injury
adverse drug
risk assessment
transcription factor
emergency department